Total Payments
$25,724
2024 Payments
$3,422
Companies
62
Transactions
343
Medicare Patients
24,958
Medicare Billing
$4.6M
Payment Breakdown by Category
Consulting$16,429 (63.9%)
Food & Beverage$6,344 (24.7%)
Other$2,482 (9.6%)
Education$392.93 (1.5%)
Travel$77.23 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $16,429 | 14 | 63.9% |
| Food and Beverage | $6,344 | 317 | 24.7% |
| Honoraria | $2,482 | 2 | 9.6% |
| Education | $392.93 | 6 | 1.5% |
| Travel and Lodging | $77.23 | 4 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $3,705 | 18 | $0 (2022) |
| BeiGene USA, Inc. | $1,950 | 1 | $0 (2024) |
| Heron Therapeutics, Inc. | $1,879 | 4 | $0 (2018) |
| Kite Pharma, Inc. | $1,716 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $1,697 | 15 | $0 (2024) |
| Janssen Biotech, Inc. | $1,607 | 14 | $0 (2023) |
| Genentech USA, Inc. | $1,412 | 4 | $0 (2022) |
| TESARO, Inc. | $1,409 | 16 | $0 (2019) |
| Gilead Sciences, Inc. | $1,395 | 6 | $0 (2022) |
| Karyopharm Therapeutics Inc. | $1,364 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,422 | 21 | BeiGene USA, Inc. ($1,950) |
| 2023 | $300.32 | 11 | Astellas Pharma US Inc ($112.88) |
| 2022 | $3,571 | 36 | Kite Pharma, Inc. ($1,690) |
| 2021 | $6,017 | 39 | Celgene Corporation ($1,570) |
| 2020 | $1,961 | 41 | Karyopharm Therapeutics Inc. ($1,325) |
| 2019 | $1,930 | 48 | TESARO, Inc. ($1,102) |
| 2018 | $5,142 | 53 | Celgene Corporation ($2,020) |
| 2017 | $3,382 | 94 | Janssen Biotech, Inc. ($1,442) |
All Payment Transactions
343 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $25.30 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.50 | General |
| 11/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $25.86 | General |
| 10/08/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 08/27/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $25.65 | General |
| Category: Oncology | ||||||
| 08/26/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Spectrum Pharmaceuticals Inc. | ROLVEDON (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $28.16 | General |
| Category: Oncology | ||||||
| 07/23/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $19.66 | General |
| 07/16/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $26.18 | General |
| Category: Hematology | ||||||
| 06/25/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.51 | General |
| Category: Hematology/Oncology | ||||||
| 06/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: ONCOLOGY | ||||||
| 06/04/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: Oncology | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 04/16/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Oncology | ||||||
| 03/19/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: Oncology | ||||||
| 03/05/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: Oncology | ||||||
| 01/16/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $25.24 | General |
| 12/19/2023 | Shield Therapeutics Inc | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: Hematology | ||||||
| 12/19/2023 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: Hematology | ||||||
| 12/12/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 4,082 | 60,360 | $879,234 | $280,256 |
| 2022 | 48 | 5,192 | 346,283 | $4.4M | $1.4M |
| 2021 | 59 | 8,368 | 334,350 | $2.0M | $1.6M |
| 2020 | 54 | 7,316 | 297,747 | $1.7M | $1.3M |
Total Patients
24,958
Total Services
1,038,740
Medicare Billing
$4.6M
Procedure Codes
188
All Medicare Procedures & Services
188 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 502 | 850 | $311,967 | $98,207 | 31.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 41 | 47,250 | $130,410 | $40,100 | 30.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 183 | 183 | $88,233 | $27,483 | 31.1% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 43 | 4,500 | $91,353 | $26,892 | 29.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 131 | 194 | $50,586 | $15,980 | 31.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 646 | 1,666 | $39,168 | $12,678 | 32.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 635 | 1,567 | $24,505 | $11,678 | 47.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 24 | 72 | $28,325 | $8,415 | 29.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 50 | 96 | $18,456 | $4,933 | 26.7% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 25 | 27 | $12,443 | $4,415 | 35.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 252 | 318 | $10,471 | $4,248 | 40.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 310 | 408 | $10,447 | $4,223 | 40.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 115 | 316 | $12,927 | $3,771 | 29.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 24 | 115 | $9,729 | $3,201 | 32.9% |
| 83550 | Iron binding capacity | Office | 2023 | 254 | 320 | $6,756 | $2,742 | 40.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 84 | 117 | $7,921 | $2,273 | 28.7% |
| 83540 | Iron level | Office | 2023 | 255 | 331 | $5,165 | $2,099 | 40.6% |
| 85097 | Bone marrow, smear interpretation | Office | 2023 | 24 | 26 | $4,984 | $1,664 | 33.4% |
| 84100 | Phosphate level | Office | 2023 | 243 | 306 | $3,512 | $1,423 | 40.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 46 | 86 | $3,930 | $1,293 | 32.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 33 | $2,756 | $772.23 | 28.0% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 22 | 66 | $1,388 | $601.48 | 43.3% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 49 | 147 | $1,499 | $466.62 | 31.1% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 11 | 21 | $1,214 | $399.21 | 32.9% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 69 | 131 | $598.77 | $153.85 | 25.7% |
About Dr. Mikhail Grinberg, MD
Dr. Mikhail Grinberg, MD is a Hematology & Oncology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1013917400.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mikhail Grinberg, MD has received a total of $25,724 in payments from pharmaceutical and medical device companies, with $3,422 received in 2024. These payments were reported across 343 transactions from 62 companies. The most common payment nature is "Consulting Fee" ($16,429).
As a Medicare-enrolled provider, Grinberg has provided services to 24,958 Medicare beneficiaries, totaling 1,038,740 services with total Medicare billing of $4.6M. Data is available for 4 years (2020–2023), covering 188 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Brooklyn, NY
- Active Since 07/28/2005
- Last Updated 11/16/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1013917400
Products in Payments
- Revlimid (Drug) $2,115
- BRUKINSA (Drug) $1,950
- SUSTOL (Drug) $1,879
- Yescarta (Drug) $1,716
- IMBRUVICA (Drug) $1,380
- Trodelvy (Drug) $1,365
- XPOVIO (Drug) $1,364
- ZEJULA (Drug) $1,203
- AYVAKIT (Drug) $1,182
- ELIGARD (Drug) $1,038
- IMFINZI (Biological) $525.00
- LYNPARZA (Drug) $525.00
- TAGRISSO (Drug) $467.59
- OPDIVO (Biological) $305.68
- Imbruvica (Drug) $293.09
- SIR-Spheres Microspheres (Device) $243.03
- VARUBI (Drug) $206.18
- KEYTRUDA (Biological) $205.67
- JAKAFI (Drug) $165.17
- Xtandi (Drug) $156.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brooklyn
Perry Cook, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Yiwu Huang, Md, MD
Hematology & Oncology — Payments: $268,275
Hematology & Oncology $268,275
Dr. Ilya Blokh, M.d, M.D
Hematology & Oncology — Payments: $191,276
Hematology & Oncology $191,276
Songchuan Guo, M.d, M.D
Hematology & Oncology — Payments: $106,907
Hematology & Oncology $106,907
Yiqing Xu, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $51,145
Hematology & Oncology $51,145
Dr. Azriel Hirschfeld, M.d, M.D
Hematology & Oncology — Payments: $48,699
Hematology & Oncology $48,699